The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid-Reference-Cited by-同舟云学术

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Published:2007-03-15 Issue:6 Volume:109 Page:1090-1096
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Oh William K.,Proctor Kevin,Nakabayashi Mari,Evan Carolyn,Tormey Lauren K.,Daskivich Timothy,Antràs Lucia,Smith Michael,Neary Maureen P.,Duh Mei Sheng

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

2. Bone metastases: Approaches to management

3. Skeletal complications of malignancy

4. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

5. Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of methods used in prediction models with recurrent event data;2024-03-14

2. Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study;Endocrine;2023-11-16

3. Renal Safety of Zoledronic Acid in Patients with Osteoporosis: A Retrospective Study;2023-07-12

4. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials;Journal of Orthopaedic Surgery and Research;2021-06-22

5. Bisphosphonate nephropathy: A case series and review of the literature;British Journal of Clinical Pharmacology;2021-03-04